SCHEMBL5223327

SCHEMBL5223327

COC(=O)c1ccc(NC(=O)c2ccc(C(C)(C)C)cc2)c(NC(=O)c2ccc(OC)cc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.68
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
MAPT P10636 6/20 0.61
ALDH1A1 P00352 5/20 0.56
LMNA P02545 3/20 0.56
ALOX15 P16050 1/20 0.56
APEX1 P27695 1/20 0.56
MAPK1 P28482 1/20 0.56
RECQL P46063 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 5/20 0.55
HPGD P15428 4/20 0.55
POLB P06746 1/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPY1R P25929 1/20 0.55
NPY2R P49146 1/20 0.55
NR1H4 Q96RI1 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5308412 1.00 F10 (0.68) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL7251219 0.92 F10 (0.79) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL5221860 0.91 F10 (0.83) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL5221185 0.90 MEN1 (0.84) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL5224928 0.90 MEN1 (0.84) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL7407190 0.84 F10 (0.68) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL7404902 0.84 F10 (0.68) F10MEN1KMT2AMAPTALDH1A1
Hydrochloric Acid SCHEMBL6542561 0.84 MAPT (0.49) F10MEN1KMT2AMAPTALDH1A1
SCHEMBL6108626 0.82 KDM4E (0.68) KMT2AMAPTALDH1A1LMNAHSD17B10
SCHEMBL9132247 0.82 HPGD (0.62) MAPTALDH1A1LMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 F10 12/4885MEN1 1119/4885KMT2A 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.